Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nevis Brands Inc PSCBF


Primary Symbol: C.NEVI

Consumer Defensive Household & Personal Products
Nevis Brands Inc., formerly Pascal Biosciences Inc., provides cannabis brands throughout the United States. The Company provides products in Washington, Oregon, California, Ohio, Arizona and Colorado through partners and licensees. Its products include Major, which is a cannabis beverage. Major is a high-dose tetrahydrocannabinol (THC) beverage that delivers a consistent cannabis experience... see more

Recent & Breaking News (CSE:NEVI)

Pascal Biosciences Announces Formation of Clinical Advisory Board

GlobeNewswire May 8, 2019

Pascal Biosciences Provides Corporate Update for First Quarter of 2019

GlobeNewswire April 23, 2019

Pascal Biosciences names Carl Weissman acting President

GlobeNewswire April 1, 2019

Pascal Biosciences Partners with Mitacs to Support Innovative Cancer Research at University of British Columbia

GlobeNewswire March 18, 2019

Pascal Biosciences Commences Cannabinoid Testing of Human Volunteers and Patients

GlobeNewswire January 24, 2019

Pascal Biosciences Provides Year-End Investor Update and Reviews Upcoming Milestones

GlobeNewswire December 20, 2018

 Pascal Biosciences Announces Year-End Investor Update Webcast

GlobeNewswire December 10, 2018

Pascal Biosciences Expands Leadership Team to Support Strategic Advancement of Its Cannabinoid Based Programs

GlobeNewswire November 28, 2018

CFN Media's Exclusive Interview with Pascal Biosciences

GlobeNewswire November 8, 2018

Pascal Biosciences Announces Optimization of Cannabinoid-Derived Drug Candidates to Kill Glioblastoma Cells

GlobeNewswire November 5, 2018

Pascal Biosciences and the University of Washington Enter Into Exclusive License Agreement to Develop Cannabinoid-based Medicine for Cancer

GlobeNewswire October 30, 2018

Cannabinoids May Do More Than Manage Cancer Symptoms -- CFN Media

GlobeNewswire July 24, 2018

Pascal Biosciences appoints Julie M. Eastland, accomplished financial executive, to Board of Directors

GlobeNewswire July 16, 2018

Pascal Biosciences: Cannabinoids Could Play a Role in Destroying Cancer Cells -- CFN Media

GlobeNewswire July 3, 2018

CORRECTING and REPLACING -- Pascal Biosciences Engages CFN Media to Build New Investor Audience -- CFN Media

GlobeNewswire June 19, 2018

Pascal Biosciences Engages CFN Media to Build New Investor Audience

GlobeNewswire June 19, 2018

Pascal Biosciences Receives DEA Schedule I License for Cannabinoid Development and Renews UBC Collaboration

GlobeNewswire June 18, 2018

Pascal Announces Oversubscription of Financing

GlobeNewswire March 8, 2018

Pascal Biosciences Inc. Announces Non-Brokered Private Placement

GlobeNewswire February 23, 2018

Pascal Biosciences Identifies Molecules in Cannabis That Stimulate the Immune System to Destroy Tumor Cells

GlobeNewswire February 21, 2018